Obstetrics and Gynecology Clinics of North America35 (2008) ppt

[...]... levels did not differ between the 3- and 4-day HFI groups Schlaff and colleagues [12] compared three groups of patients taking (1) a standard 21/7 regimen of EE, 20 mg, and levonorgestrel, 100 mg; or (2) a continuous regimen of 28 days of EE, 20 mg, plus desogestrel, 150 mg, with no HFI; or (3) 21 days of EE, 20 mg, plus desogestrel, 150 mg, with 2 placebo days and 5 days of EE, 10 mg Subjects using the... (2008) 199–217 Human Papilloma Virus – Prevention and Treatment Maria Lina Diaz, MD Section of Ambulatory Gynecology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, FL 33331, USA The accumulated wealth of information and knowledge regarding the relationship between the human papilloma virus (HPV) and many diseases continues to expand This has been fueled in part by the development of. .. disorders such as von Willebrand’s syndrome [25] are all off-label uses of OCPs Management of pelvic pain caused by dysmenorrhea, of ovulatory pain, and of endometriosis, as well as skin conditions such as acne and hirsutism [26], also are common indications for oral contraceptive use As women are delay child bearing, the risks of ovarian and endometrial cancer increase Estrogen and progestin contraceptives... retrospective cohort study of primiparous women Am J Obstet Gynecol 2001;184:881–90 Obstet Gynecol Clin N Am 35 (2008) 185–197 New Forms of Contraception Kristen A Plastino, MDa,*,1, Patricia J Sulak, MDb,2 a Department of Obstetrics & Gynecology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA b Department of Obstetrics & Gynecology, Texas A&M... cardiovascular events was noted, resulting in dramatic lowering of estrogen and progestin doses and eventual removal of high-dose formulations from the market The approach remains, after 40 years, to use the lowest doses of steroids to provide the most effective contraception The standard regimen of hormonal contraception has been 21 days of estrogen and progestin components followed by 7 hormone-free days... initiate systemic HT in the absence of contraindications in postmenopausal women who have FSD [21] The role of androgens in the treatment of FSD is controversial Testosterone has been linked to sexual desire [10,18,19,21] Androgen levels gradually decrease with age starting at about 30 years, but there is no abrupt drop at the time of menopause Ovarian and adrenal production of androgens continue into the... suppression The FDA has approved two oral contraceptives that shorten the HFI to 4 days and increase the active component to 24 days One contains 20 mg of EE and 3 mg of drospirenone The other contains 20 mg of EE and 1 mg of norethindrone Knowing that some women may want fewer scheduled withdrawal bleeds in a year and that the HFI and withdrawal bleeding during this time is unnecessary, many practitioners used... dosing, and improved bleeding profiles also were observed [14] This experience led to the development of an FDAapproved continuous OCP regimen in 2006 This regimen contained 150 mg of levonorgestrel and 30 mg of EE for 84 days followed by 7 days of low-dose EE (10 mg), again allowing four withdrawal bleeds per year but improving the bleeding profile A prospective, randomized study of 21/7, 84/7, and 84/7... those who have history of sexual abuse usually require psychotherapy Alteration of contributors to FSD, such as smoking, excess alcohol or illicit drug use, obesity, and optimal treatment of medical diseases that can affect FSD such as hypertension and diabetes are also part of management Simple things, including exercise, a healthy diet, and adequate rest, improve physical and mental, and therefore sexual... regulate cycles, improve complexion, and decrease cancer risks Women can expect more from their contraception besides birth control and have many more options today than in the past New formulations of combined estrogen and progestin regimens have deviated from the standard regimen of 21 active pills and 7 days of placebos to decrease monthly hormone-withdrawal symptoms and withdrawal bleeding Also, women . the individual and community-based health of women of all ages. This issue of the Obstetrics and Gynecology Clinics of North America pertains to office gynecology, reflecting the expanding outpatient. physician. This edition of Obstetrics and Gynecology Clinics of North America explores many of the daily challenges of office practice. Updates in new contraceptive options and in management of dysfunctional. are expanded upon. As women age, osteoporosis and fecal incontinence limit the quality of life of many of our patients. Understanding management strategies is a goal of this edition. One of the most